PDF herunterladen
Arthritis und Rheuma 2018; 38(01): 50-55
DOI: 10.1055/s-0038-1637691
Kinderrheumatologie
Schattauer GmbH

Aktuelle Leitlinie zur Therapie der Uveitis bei juveniler idiopathischer Arthritis

Current treatment guideline on uveitis in juvenile idiopathic arthritis
A. Heiligenhaus
1   F.E.B.O., Uveitis-Zentrum, Augenzentrum am St. Franziskus Hospital, Münster
,
K. Minden
2   Charité – Universitätsmedizin Berlin, Medizinische Klinik mit SP Rheumatologie und Klinische Immunologie und Deutsches Rheumaforschungszentrum, Berlin
,
C. Tappeiner
3   F.E.B.O., Universitätsklinik für Augenheilkunde, Inselspital, Bern, Schweiz
,
H. Lehmann   *
4   Allgemeine Pädiatrie und Rheumatologie, Universitätsklinikum Gießen
,
Leitliniengruppe › Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. April 2018 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Zielsetzung: Aktualisierung der bestehenden deutschsprachigen interdisziplinären Leitlinie zur Therapie der juvenilen idiopathischen Arthritis (JIA)-assoziierten Uveitis aufgrund der aktuellen Literatur.

Material und Methoden: Die Leitliniengruppe bestand aus Delegierten der Deutschen Ophthalmologischen Gesellschaft, der Gesellschaft für Kinder- und Jugendrheumatologie, der Deutschen Gesellschaft für Rheumatologie, des Berufsverbandes der Augenärzte Deutschlands und Patientenvertretern. Die Methodik umfasste eine systematische Literaturrecherche, eine Graduierung von Evidenz und Empfehlungen, eine Konsensusfindung mittels nominalem Gruppenprozess und Delphirunden und eine externe Begutachtung.

Ergebnisse: Entsprechend dem individuellen Schweregrad der Uveitis kann eine qualitative hochwertige Versorgung der Patienten erzielt werden. Berücksichtigung finden Kortikosteroide, konventionell synthetische (cs) und biologische (b) disease-modifying anti-rheumatic drugs (DMARDs), einschließlich TNF-α-Inhibitoren (z. B. Adalimumab, Golimumab, Infliximab), Tocilizumab, Abatacept und Rituximab.

Schlussfolgerungen: Mit der Leitlinie wird ein aktueller Therapiealgorithmus mit Darstellung als Flussdiagramm erarbeitet.

Summary

Goal: Revision of the German interdisciplinary guideline on the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis with appreciation of recently published data.

Material and methods: The guideline group comprised delegates from German Ophthalmological Society, Society for Child and Adolescent Rheumatology, German Society of Rheumatology, Professional Association of Ophthalmologists, and patient representatives. Methods included systematic literature survey, gradation of evidence and recommendations, consensus process (Delphi procedure), and external review.

Results: Adjusted to disease severity in the individual case, a high-quality patient care can be ensured. Corticosteroids, conventional synthetic (cs) and biological (b) disease-modifying anti-rheumatic drugs (DMARDs) are taken into account, including TNFα inhibitors (e. g. adalimumab, golimumab, infliximab), tocilizumab, abatacept and rituximab.

Conclusions: Within the guideline, a current treatment algorithm with presentation as flow diagrams is established.

Schlüsselwörter

Juvenile idiopathische Arthritis - Therapie - Uveitis

Keywords

Juvenile idiopathic arthritis - treatment - uveitis

* Leitliniengruppe: Heiligenhaus Aa, Minden Kb, Tappeiner Ca, Baus He, Bertram Bc, Deuter Ca, Foeldvari Ib, Föll Db, Frosch Mb, Ganser Gb, Gaubitz Md, Günther Ab, Heinz Ca, Horneff Gb, Huemer Cb, Kopp If, Lommatzsch Ca, Lutz Tb, Michels Hb, Neß Ta, Neudorf Ub, Pleyer Ua, Schneider Md, Schulze-Koops Hd, Thurau Sa, Zierhut Ma, Lehmann HWb.


Leitlinie der Deutschen Ophthalmologischen Gesellschaft (DOG)a und der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)b unter Mitwirkung folgender Fachgesellschaften: Berufsverband der Augenärzte (BVA)c, Deutsche Gesellschaft für Rheumatologie (DGRh)d, Patientengruppe an Uveitis erkrankter Kinder und deren Familiene, AWMFf.


 

  • Literatur

  • 1 Heiligenhaus A, Niewerth M, Ganser G. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nationwide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015-1019.
    CrossrefPubMedGoogle Scholar
  • 2 Kotaniemi K, Kautiainen H, Karma A. et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071-2075.
    CrossrefPubMedGoogle Scholar
  • 3 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516.
    CrossrefPubMedGoogle Scholar
  • 4 De Boer J, Steijaert A, van den Bor R. et al. Development of macular edema and impact and visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67-73.
    CrossrefPubMedGoogle Scholar
  • 5 Böhm MR, Tappeiner C, Breitbach MA. et al. Ocular hypotony in patients with juvenile idiopathic arthritis- associated uveitis. Am J Ophthalmol 2017; 173: 45-55.
    CrossrefPubMedGoogle Scholar
  • 6 Thorne JE, Woreta FA, Dunn JP. et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436-1441.
    CrossrefPubMedGoogle Scholar
  • 7 Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485.
    CrossrefPubMedGoogle Scholar
  • 8 De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884.
    CrossrefPubMedGoogle Scholar
  • 9 Heiligenhaus A, Michels H, Schumacher C. et al. Evidence-based guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012; 32: 1121-1133.
    CrossrefPubMedGoogle Scholar
  • 10 Kothari S, Foster CS, Pistilli M. et al. The risk of intraocular pressure elevation in pediatric non-infectious uveitis. Ophthalmology 2015; 122: 1987-2001.
    CrossrefPubMedGoogle Scholar
  • 11 Tappeiner C, Klotsche J, Schenck S. et al. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-944.
    PubMedGoogle Scholar
  • 12 Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365.
    Google Scholar
  • 13 Heiligenhaus A, Mingels A, Heinz C. et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748.
    CrossrefPubMedGoogle Scholar
  • 14 Samson CM, Waheed N, Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139.
    CrossrefPubMedGoogle Scholar
  • 15 Kostik MM, Gaidar EV, Hynnes AY. et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol 2016; 34: 714-718.
    PubMedGoogle Scholar
  • 16 Papadopoulou C, Kostik M, Böhm M. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-884.
    CrossrefPubMedGoogle Scholar
  • 17 Tappeiner C, Schenck S, Niewerth M. et al. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res 2016; 68: 46-54.
    CrossrefPubMedGoogle Scholar
  • 18 Lerman MA, Burnham JM, Chang PY. et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013; 40: 1394-1403.
    CrossrefPubMedGoogle Scholar
  • 19 Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200.
    CrossrefPubMedGoogle Scholar
  • 20 Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 2014; 22: 96-101.
    CrossrefPubMedGoogle Scholar
  • 21 Simonini G, Druce K, Cimaz R. et al. Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66: 1073-1084.
    CrossrefPubMedGoogle Scholar
  • 22 Vallet H, Seve P, Biard L. et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 2016; 68: 1522-1530.
    CrossrefPubMedGoogle Scholar
  • 23 Beukelman T, Ringold S, Davis TE. et al. Diseasemodifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012; 39: 1867-1874.
    CrossrefPubMedGoogle Scholar
  • 24 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopahic arthritis. N Engl J Med 2017; 376: 1637-1646.
    CrossrefPubMedGoogle Scholar
  • 25 Diaz-Llopis M, Salom D, Garcia-de-Vicuna C. et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-1581.
    CrossrefPubMedGoogle Scholar
  • 26 Zannin ME, Birolo C, Gerloni VM. et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013; 40: 74-79.
    CrossrefPubMedGoogle Scholar
  • 27 Cordero-Coma M, Calvo-Rio V, Adan A. et al. Golimumab as rescue therapy for refractory immunemediated uveitis: a three-center experience. Mediators Inflamm 2014; 2014: 717598.
    CrossrefPubMedGoogle Scholar
  • 28 Miserocchi E, Modorati G, Pontikaki I. et al. Longterm treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90-95.
    CrossrefPubMedGoogle Scholar
  • 29 Tynjälä P, Lindahl P, Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550.
    PubMedGoogle Scholar
  • 30 Saurenmann RK, Levin AV, Feldman BM. et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833-836.
    CrossrefPubMedGoogle Scholar
  • 31 Scrivo R, Spadaro A, Spinelli FR. et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-1556.
    CrossrefPubMedGoogle Scholar
  • 32 Calvo-Rio V, Santos-Gomez M, Calvo I. et al. Anti- IL-6R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy. A multicenter study of 25 patients. Arthritis Rheumatol 2016; 69: 668-675.
    CrossrefPubMedGoogle Scholar
  • 33 Tappeiner C, Mesquida M, Adan A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43: 2183-2188.
    CrossrefPubMedGoogle Scholar
  • 34 Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 2008; 35: 1897-1898.
    Google Scholar
  • 35 Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Arthritis Care Res 2011; 63: 307-310.
    CrossrefGoogle Scholar
  • 36 Tappeiner C, Miserocchi E, Bodaghi B. et al. Abatacept in the treatment of severe, longstanding and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706-711.
    CrossrefPubMedGoogle Scholar
  • 37 Heiligenhaus A, Miserocchi E, Heinz C. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390-1394.
    CrossrefPubMedGoogle Scholar
  • 38 Miserocchi E, Pontikaki I, Modorati G. et al. Rituximab for uveitis. Ophthalmology 2011; 118: 223-224.
    CrossrefPubMedGoogle Scholar
  • 39 Miserocchi E, Modorati G, Berchicci L. et al. Longterm treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016; 100: 782-786.
    CrossrefPubMedGoogle Scholar
  • 40 Kalinina VKAyuso, van de Winkel EL, Rothova A. et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-222.
    CrossrefPubMedGoogle Scholar